Alkami Kicks Off Sale Talks Amid Pressure from Activist Investor Jana Partners
The $2B digital banking software firm is in early talks with private equity firms.
Already have an account? Sign in.
The $2B digital banking software firm is in early talks with private equity firms.
Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.
MarineMax will be bought by Safe Harbor for $1.5 billion, giving shareholders $53 per share and taking the company private.
Tenax’s heart drug trial missed its main goal, but showed promise in sicker patients, sending shares down more than 85%.